SG/CALL/ELI LILLY & CO/960/0.1/20.09.24 | Real-time Bid/Ask 16:42:36 13/05/2024 BST | ||
| 0.87 EUR / 0.89 EUR | -20.72% |
|
| Current month | -2.63% | ||
| 1 month | -34.71% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
More news
| Date | Price | Change | Volume |
|---|---|---|---|
| 13/05/24 | 0.98 | -11.71% | 0 |
| 10/05/24 | 1.11 | -7.50% | 0 |
| 09/05/24 | 1.2 | -6.98% | 0 |
| 08/05/24 | 1.29 | +20.56% | 0 |
| 07/05/24 | 1.07 | +33.75% | 0 |
Delayed Quote Börse Stuttgart
Last update May 13, 2024 at 08:24 am
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
Société Générale
|
| WKN | SU92X0 |
| ISIN | DE000SU92X06 |
| Date issued | 29/02/2024 |
| Strike | 960 $ |
| Maturity | 20/09/2024 (130 Days) |
| Parity | 10 : 1 |
| Emission price | 2.12 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 2.97 € |
|---|---|
| Lowest since issue | 0.8 € |
| Spread | 0.02 € |
| Spread % | 2.33% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
760
USD
Average target price
850.4
USD
Spread / Average Target
+11.90%
- Stock Market
- Warrants
- Warrant
